Usefulness of Neutrophil-to-Lymphocyte Ratio in Risk Stratification of Patients With Advanced Heart Failure

Vicente A. Benites-Zapata, MD^a, Adrian V. Hernandez, MD, PhD^{b,c}, Vijaiganesh Nagarajan, MD, MRCP^d, Clay A. Cauthen, MA, MD^e, Randall C. Starling, MD, MPH^f, and W.H. Wilson Tang, MD^{f,*}

Elevated neutrophil-to-lymphocyte ratio (NLR) has been associated with increased mortality in patients with acute heart failure (HF) and neoplastic diseases. We investigated the association between NLR and mortality or cardiac transplantation in a retrospective cohort of 527 patients presented to the Cleveland Clinic for evaluation of advanced HF therapy options from 2007 to 2010. Patients were divided according to low, intermediate, and high tertiles of NLR and were followed longitudinally for time to all-cause mortality or heart transplantation (primary outcome). The median NLR was 3.9 (interquartile range 2.5 to 6.5). In univariate analysis, intermediate and highest tertiles of NLR had a higher risk than the lowest tertile for the primary outcome and all-causes mortality. Compared with the lowest tertile, there was no difference in the risk of heart transplantation for intermediate and high tertiles. In multivariate analysis, compared with the lowest tertile, the intermediate and high NLR tertiles remained significantly associated with the primary outcome (hazard ratio [HR] = 1.61, 95% confidence interval [CI] 1.10 to 2.37 and HR = 1.55, 95% CI 1.02 to 2.36, respectively) and all-cause mortality (HR = 1.83, 95% CI 1.07 to 3.14 and HR = 2.16, 95% CI 1.21 to 3.83, respectively). In conclusion, elevated NLR is associated with increased mortality or heart transplantation risk in patients with advanced HF. © 2015 Elsevier Inc. All rights reserved. (Am J Cardiol 2015;115:57–61)

Lymphocytopenia has long been associated with poor prognosis in heart failure (HF).^{1,2} Several studies over the past few decades have demonstrated the potential of neutrophil-to-lymphocyte ratio (NLR), a widely available hematologic marker of oxidative stress damage, to serve as a good prognostic marker of mortality in cardiac and noncardiac diseases.^{3–7} In this study, we evaluated the association between NLR and future risk of mortality or cardiac transplantation in a large contemporary cohort of patients with advanced HF.

Methods

We analyzed 549 consecutive patients presented to the Cleveland Clinic (Cleveland, Ohio) from 2007 to 2010 for evaluation of advanced HF therapies and consideration for heart transplantation or mechanical circulatory assist

devices. Electronic medical records were used to obtain demographic variables (age, gender, and race), clinical variables, laboratory values, and medications. Among this cohort, 527 patients had documented values of NLR within the time frame and clinical stability to complete the comprehensive evaluation for advanced HF therapeutics and were included in this study. Mortality data were obtained from social security death index (until 2012) and timing of death and heart transplantation were confirmed by review of the electronic medical records. The construction of the database was conducted by an independent researcher who was not involved in the care of patients. Data were collected retrospectively and the study was approved by the Institutional Review Board of the Cleveland Clinic.

NLR was calculated as the ratio between neutrophil count and lymphocyte count obtained at the time of evaluation. Participants were categorized in NLR tertiles low (<3.0), intermediate (3.0 to 5.4), and high (>5.4). The primary outcome was a composite of all-cause mortality or heart transplantation. Information on heart transplantation was extracted from the electronic records.

Continuous variables were described as mean and SD or median with interquartile range. Categorical variables were expressed as frequencies and percentages. Continuous variables were compared among NLR tertiles with the analysis of variance or Kruskal-Wallis tests; categorical variables were compared with the chi-square test. The Kaplan-Meier method was used to evaluate survival or freedom from events, and the log-rank test was used to evaluate differences among NLR tertiles. Univariate and multivariate Cox regression models were used to assess the association between tertiles of NLR and the primary outcome or its components. We reported crude and adjusted hazard ratios

^aUnidad de Análisis y Generación de Evidencia en Salud Pública, Instituto Nacional de Salud, Lima, Peru; ^bFaculty of Health Sciences, Postgraduate and Medical Schools, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; ^cHealth Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; ^dDepartment of Cardiovascular Medicine, University of Virginia, Charlottesville, Virginia; ^eSeton Heart Institute, Kyle, Texas; and ^fDepartment of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Manuscript received July 27, 2014; revised manuscript received and accepted October 7, 2014.

This research was supported by National Institutes of Health grant RO1 HL103931.

See page 60 for disclosure information.

*Corresponding author: Tel: (216) 444-2121; fax: (216) 445-6165.

E-mail address: tangw@ccf.org (W.H. Wilson Tang).

Table 1

Baseline characteristics of patients with severe chronic heart failure grouped in tertiles of neutrophil-to-lymphocyte ratio

Neutrophil-to-Lymphocyte ratio	Tertiles			p Value
	Low (n=176)	Intermediate (n=177)	High (n= 174)	
Variable				
Age (years)	53 (43-61)	59 (51-64)	57 (47-64)	<0.01
Male	113 (64%)	136 (77%)	134 (77%)	<0.01
Black	42 (25.4%)	18 (11.2)	20 (12.7)	<0.01
Smoke	47 (27%)	35 (20%)	32 (18 %)	0.13
Diabetes mellitus	38(22%)	53(30%)	46 (26%)	0.19
Hypertension	60 (34%)	81(46%)	77 (44%)	0.05
Dyslipidemia	74(42%)	86(49%)	64 (37%)	0.07
Non-ischemic heart failure	113 (65%)	97 (55.4%)	100 (57.8%)	0.20
Chronic obstructive pulmonary disease	15(9%)	16 (9%)	14(8%)	0.98
Coronary Artery Disease	65 (37%)	77 (44%)	84 (48%)	0.10
Stroke	13 (7%)	21 (12%)	19 (11%)	0.33
Atrial Fibrillation	61(35%)	67(38%)	66 (38%)	0.76
Ventricular Assist Device	34 (19%)	58 (33%)	60 (35%)	<0.01
Creatinine (mg/dL)	1.1 (0.9-1.4)	1.2 (1.0-1.5)	1.3 (1.0-1.8)	<0.01
Estimated glomerular filtration rate (ml/min/1.73 m ²)	85 (63-111)	81 (56-112)	68 (48-100)	<0.01
Total Protein (g/dL)	6.9 (6.3-7.4)	6.7 (6.2-7.3)	6.2 (5.3-6.9)	<0.01
Albumin (g/dL)	4.0 (3.6-4.4)	4.0 (3.4- 4.4)	3.4 (2.8-3.9)	<0.01
Bilirubin (mg/dL)	0.8 (0.5-1.2)	0.8 (0.5-1.5)	1.1 (0.7-1.8)	<0.01
Blood Urea Nitrogen (mg/dL)	20 (15-40)	24 (19-33)	29 (22-38)	<0.01
Sodium (mEq/L)	136 (134-139)	136 (134-139)	135(132-138)	<0.01
B-type Natriuretic Peptide (pg/mL)	454 (102-804)	498 (225-956)	619 (244-1224)	<0.01
Platelets (10 ³ /μL)	193 (155-244)	194 (164-231)	173 (127-223)	<0.01
Platelet -to-lymphocyte ratio	104 (77-134)	157 (118-211)	222 (152-335)	<0.01
Mean Platelet Volume (fL)	10.5 (9.9-11.0)	10.4 (9.8-11.2)	10.2 (9.7-11.0)	0.21
Neutrophil-to-lymphocyte ratio	2.1 (1.6-2.5)	3.9 (3.4-4.8)	8.1 (6.5-12.4)	<0.01
Aspirin	94 (53%)	109 (62%)	94 (54%)	0.20
Beta-blocker	118 (67%)	130 (74%)	87 (50%)	<0.01
Angiotensin-converting enzyme Inhibitors	101 (57%)	80 (46%)	59 (34%)	<0.01
Clopidogrel	29(17%)	27(15%)	22 (13%)	0.60
Spiroonolactone	85(48%)	90 (52%)	67 (39%)	0.05
Hydralazine	33 (19%)	50 (28%)	50 (29%)	0.05
Nitrates	46 (26%)	53 (30%)	56 (32%)	0.45
Angiotensin II receptor blocker	21(12%)	24 (14%)	16 (9%)	0.43
Warfarin	64 (36%)	63 (36%)	62 (36%)	0.99

Continuous variables are expressed as median (interquartile range).

Figure 1. Distribution of NLR stratified according to gender.

Number at risk

Tertiles=1	170	92	39	11	0
Tertiles=2	167	74	25	3	0
Tertiles=3	157	64	27	8	0

Figure 2. Kaplan-Meier curves comparing freedom from death or heart transplantation among NLR ratio tertiles in patients with advanced HF.

(HRs) with their 95% confidence intervals (CIs). Variables with $p < 0.2$ in univariate analysis were considered candidates to enter into the multivariate model along with age, gender, and race. The variable mechanical circulatory assist device was analyzed as a time-dependent variable. Analyses were conducted in STATA version 11.0 (StataCorp LP, College Station, Texas).

Results

Of the 527 patients, 176, 177, and 174 patients were in the lowest, intermediate, and higher NLR tertile, respectively. Baseline characteristics of the patients across NLR tertiles are listed in Table 1. Overall, NLR correlated directly with B-type natriuretic peptide ($r = 0.14$, $p < 0.01$). There was no correlation between NLR and left ventricular ejection fraction, peak oxygen consumption, and hemodynamic variables. The distribution of the logarithm of NLR is presented in Figure 1, stratified according to gender (mean $\pm$ SD, NLR men 5.9 ± 6.3 vs women 5.5 ± 8.4 , $p = 0.6$).

Table 2
Univariate and multivariate Cox models for the primary and secondary outcomes

Outcomes	NLR Tertiles	Crude HR (95% CI)	p value	Adjusted HR (95% CI)	p value
All-cause Mortality or Heart* Transplantation	Higher	1.93 (1.42-2.63)	<0.01	1.55 (1.02-2.36)	0.04
	Intermediate	1.42 (1.03-1.96)	0.03	1.61 (1.10-2.37)	0.02
	Lower	1	–	1	–
All-cause Mortality [†]	Higher	2.57 (1.72-3.85)	<0.01	2.16 (1.21-3.83)	<0.01
	Intermediate	1.56 (1.01-2.40)	0.04	1.83 (1.07-3.14)	0.03
	Lower	1	–	1	–
Heart Transplantation [‡]	Higher	1.05 (0.66-1.66)	0.84	0.80 (0.47-1.43)	0.43
	Intermediate	1.15 (0.74-1.76)	0.54	1.10 (0.68-1.84)	0.71
	Lower	1	–	1	–

* Adjusted for: Age, sex, black race, cigarette smoker, diabetes, coronary artery disease, atrial fibrillation, ventricular assist device, albumin, bilirubin, blood urea nitrogen, sodium, brain natriuretic peptide, platelets, aspirin, beta-blocker, angiotensin-converting enzyme inhibitors and hydralazine.

[†] Adjusted for: Age, sex, black race, diabetes, hypertension, No ischemic failure, chronic obstructive pulmonary disease, coronary artery disease, stroke, atrial fibrillation, ventricular assist device, creatinine, estimated glomerular filtration rate albumin, blood urea nitrogen, brain natriuretic peptide, platelets and beta-blocker.

[‡] Adjusted for: Age, black race, cigarette smoker, hypertension, dyslipidemia, no ischemic failure, chronic obstructive pulmonary disease, stroke, ventricular assist device, albumin, sodium, mean platelet volume, aspirin, beta-blocker, angiotensin-converting enzyme inhibitors and hydralazine. Model stratified by gender.

Number at risk					
Tertiles=1	175	121	68	25	0
Tertiles=2	174	112	50	14	0
Tertiles=3	164	94	54	22	0

Figure 3. Kaplan-Meier curves comparing survival among NLR tertiles in patients with advanced HF.

Over a median follow-up period of 11.3 (interquartile range 3.4 to 21.1) months, the primary outcome occurred in 263 patients (50%), 121 patients were transplanted (23%), and 158 patients died during follow-up (30%). In univariate analysis, NLR was associated with the primary end point ($p < 0.01$, Figure 2). In comparison to the lowest tertile, the intermediate and high tertiles of NLR had higher risk for the primary outcome. In multivariate analysis, and compared with the lowest tertile, the intermediate and highest NLR tertiles were associated with the primary outcome (HR = 1.61, 95% CI 1.10 to 2.37 and HR = 1.55, 95% CI 1.02 to 2.36, respectively; Table 2). Compared with the lowest tertile, the intermediate and highest tertiles of NLR had increased risk of all-cause mortality in univariate analysis (Figure 3). In multivariate analysis and compared with the

Number at risk					
Tertiles=1	171	94	40	11	0
Tertiles=2	169	85	27	3	0
Tertiles=3	166	70	28	8	0

Figure 4. Kaplan-Meier curves comparing freedom from heart transplantation among NLR tertiles in patients with advanced HF.

lowest tertile, the intermediate and high NLR tertiles remained significantly associated with all-causes mortality (HR = 1.83, 95% CI 1.07 to 3.14 and HR = 2.16, 95% CI 1.21 to 3.83, respectively; Table 2). No association between NLR and heart transplantation was observed in univariate analysis or multivariate analysis (Table 2, Figure 4). We did not find an association between lymphocyte or neutrophil counts with all-cause mortality in models using the same set of confounders of our primary analyses (Table 3).

Discussion

The key finding of this analysis is that patients with advanced HF and higher levels of NLR portend higher mortality or heart transplantation risk. This association was

Table 3

Multivariate Cox models for the primary and secondary outcomes and neutrophil and lymphocyte tertiles

Outcomes	Tertiles	Neutrophil Crude HR (95% CI)	Neutrophil Adjusted HR (95% CI)	p value	Lymphocyte Crude HR (95% CI)	Lymphocyte Adjusted HR (95% CI)	p value
All-cause Mortality or Heart Transplantation*	Higher	1.15 (0.83-1.60)	1.10 (0.74-1.62)	0.65	0.45 (0.33-0.62)	0.53 (0.35-0.81)	<0.01
	Intermediate	1.42 (1.05-1.94)	1.47 (1.04-2.08)	0.03	0.57 (0.42-0.77)	0.63 (0.44-0.90)	<0.01
	Lower	1	1	—	1	1	—
All-cause Mortality†	Higher	1.44 (0.97-2.14)	1.39 (0.84-2.31)	0.20	0.59 (0.39-0.88)	0.96 (0.54-1.69)	0.88
	Intermediate	1.16 (0.78-1.75)	1.05 (0.65-1.69)	0.85	0.68 (0.46-0.99)	0.96 (0.60-1.55)	0.87
	Lower	1	1	—	1	1	—
Heart Transplantation‡	Higher	0.67 (0.38-1.17)	0.56 (0.31-1.00)	0.05	0.46 (0.28-0.76)	0.45 (0.26-0.80)	<0.01
	Intermediate	1.59 (1.03-2.47)	1.64 (1.04-2.58)	0.03	0.60 (0.38-0.94)	0.64 (0.33-0.87)	0.01
	Lower	1	1	—	1	1	—

* Adjusted for: Age, sex, black race, cigarette smoker, diabetes, coronary artery disease, atrial fibrillation, ventricular assist device, albumin, bilirubin, blood urea nitrogen, sodium, brain natriuretic peptide, platelets, aspirin, beta-blocker, angiotensin-converting enzyme inhibitors and hydralazine.

† Adjusted for: Age, sex, black race, diabetes, hypertension, No ischemic failure, chronic obstructive pulmonary disease, coronary artery disease, stroke, atrial fibrillation, ventricular assist device, creatinine, estimated glomerular filtration rate albumin, blood urea nitrogen, brain natriuretic peptide, platelets and beta-blocker.

‡ Adjusted for: Age, black race, cigarette smoker, hypertension, dyslipidemia, no ischemic failure, chronic obstructive pulmonary disease, stroke, ventricular assist device, albumin, sodium, mean platelet volume, aspirin, beta-blocker, angiotensin-converting enzyme inhibitors and hydralazine. Model stratified by gender.

mainly driven by higher all-cause mortality risk, as we did not find association between NLR and heart transplantation after multivariate adjustments. Although NLR may link to mortality like several other conditions, the potential contributory role of NLR in disease progression is not supported by our analysis. Thus, it appears that NLR is more likely a risk marker than the altered composition of leukocytes being a risk mediator for advanced HF.

Several studies of NLR have been carried out in recent years in cardiac and noncardiac diseases.^{3,4} NLR has been studied in acute coronary syndromes in which an increased risk of outcomes was observed in patients with higher values of NLR. Earlier studies in acute coronary syndromes suggested strong prognostic value of NLR associated with mortality risk,⁸⁻¹⁶ whereas short- and long-term prognostic value also extended to those who underwent percutaneous coronary intervention.^{11,17-20} Independently, either neutrophilia^{21,22} or lymphopenia^{23,24} have been associated with increased mortality in acute coronary syndromes and HF, respectively. Indeed, percent lymphocyte is an independent predictor of mortality in the Seattle Heart Failure Model.^{25,26} Interestingly, NLR has been shown to be a better predictor of mortality than independent absolute neutrophil and lymphocyte counts in patients with acute decompensated HF.⁶ There is still no consensus on the cut-off points to define the levels of NLR as most studies categorized into tertiles as we did in our study. In studies of acute cardiac diseases, the median values for the higher tertile of NLR ranged between 6 and 9, where the median of our higher tertile range was found.

Why is NLR a better marker of mortality than absolute lymphocyte and neutrophil count separately? We attribute the strength of the NLR to the fact that it combines 2 different immune pathways: neutrophils are involved with a much quicker response, whereas lymphocytes are related to more adaptive long-term response of the immune system, a synonymous of physiological stress.⁴ Neutrophils produce the enzyme myeloperoxidase that is involved in

promoting phagocytic function of neutrophils, but when the levels of this enzyme are high, an excess of free radicals is produced that is responsible for tissue injury and elevated in HF.²⁷ As complete blood count is commonly ordered in patients with HF and often includes automated distributions of leukocyte subsets, the ability to risk stratify a patient population with advanced HF without additional testing is attractive.

Although ejection fraction, peak oxygen, and other hemodynamic variables are classic risk factors on mortality in HF,^{28,29} we did not find associations of these variables with NLR. This may mean that the risk of death from NLR is independent of hemodynamic variables.

Our study has several limitations. First, only baseline measurements of NLR were available that made it impossible to evaluate NLR values over time and their effect on clinical outcomes. Second, we did not have information on exact causes of death, therefore we cannot further determine if inflammation is the primary driver of disease progression leading to mortality. Third, we did not have information on some potential confounders such as nutritional status or concomitant inflammatory conditions or acuity of disease; however, we had a large number of other relevant confounding variables that served for adjustment in multivariate models. Finally, this study was conducted at a single center with high expertise in the management of severe HF and our experience may not necessarily translate to those without our wide range of advanced therapeutic options.

Disclosures

The authors have no conflicts of interest to disclose.

1. Ommen SR, Hammill SC, Gibbons RJ. The relative lymphocyte count predicts death in patients receiving implantable cardioverter defibrillators. *Pacing Clin Electrophysiol* 2002;25:1424-1428.
2. Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG, Thomson SP, Gibbons RJ. Predictive power of the relative lymphocyte

- concentration in patients with advanced heart failure. *Circulation* 1998;97:19–22.
3. Balta S, Demirkol S, Unlu M, Arslan Z, Celik T. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. *Br J Cancer* 2013;109:3125–3126.
 4. Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M, Costantino T. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. *Expert Rev Cardiovasc Ther* 2013;11:55–59.
 5. Ijsselmuiden AJ, Musters RJ, de Ruiter G, van Heerebeek L, Alderse-Baas F, van Schilfgaarde M, Leyte A, Tangelder GJ, Laarman GJ, Paulus WJ. Circulating white blood cells and platelets amplify oxidative stress in heart failure. *Nat Clin Pract Cardiovasc Med* 2008;5:811–820.
 6. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, Capodilupo R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. *Am J Cardiol* 2011;107:433–438.
 7. Tasal A, Erturk M, Uyarel H, Karakurt H, Bacaksiz A, Vatankulu MA, Turfan M, Sonmez O, Erdogan E, Ergelen M. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure. *J Cardiol* 2013;63:418–423.
 8. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Cho GY, Chae IH, Choi DJ. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol* 2013;111:636–642.
 9. Oncel RC, Ucar M, Karakas MS, Akdemir B, Yanikoglu A, Gulcan AR, Altekin RE, Demir I. Relation of neutrophil-to-lymphocyte ratio with GRACE risk score to in-hospital cardiac events in patients with ST-segment elevated myocardial infarction. *Clin Appl Thromb Hemost* 2013. <http://dx.doi.org/10.1177/1076029613505763>; in press (27 September 2013).
 10. Lee GK, Lee LC, Chong E, Lee CH, Teo SG, Chia BL, Poh KK. The long-term predictive value of the neutrophil-to-lymphocyte ratio in Type 2 diabetic patients presenting with acute myocardial infarction. *QJM* 2012;105:1075–1082.
 11. Cho KH, Jeong MH, Ahmed K, Hachinohe D, Choi HS, Chang SY, Kim MC, Hwang SH, Park KH, Lee MG, Ko JS, Sim DS, Yoon NS, Yoon HJ, Hong YJ, Kim KH, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol* 2011;107:849–856.
 12. Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, Gobunsuy R, Jadonath S, Baldari D, McCord D, Lafferty J. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. *Am J Cardiol* 2010;106:470–476.
 13. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol* 2008;102:653–657.
 14. Nunez J, Nunez E, Bodi V, Sanchis J, Minana G, Mainar L, Santos E, Merlos P, Rumiz E, Darmofal H, Heatta AM, Llacer A. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. *Am J Cardiol* 2008;101:747–752.
 15. Gazi E, Bayram B, Gazi S, Temiz A, Kirilmaz B, Altun B, Barutcu A. Prognostic value of the neutrophil-lymphocyte ratio in patients with ST-elevated acute myocardial infarction. *Clin Appl Thromb Hemost* 2013. <http://dx.doi.org/10.1177/1076029613492011>; in press (9 June 2013).
 16. Muhmmmed Suliman MA, Bahnacy Juma AA, Ali Almadhani AA, Pathare AV, Alkindi SS, Uwe Werner F. Predictive value of neutrophil to lymphocyte ratio in outcomes of patients with acute coronary syndrome. *Arch Med Res* 2010;41:618–622.
 17. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. *Am J Cardiol* 2006;97:993–996.
 18. Erkol A, Oduncu V, Turan B, Kiliçgedik A, Karabay CY, Akgün T, Güler A, Pala S, Kirma C. Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. *Am J Med Sci* 2014;348:37–42.
 19. Kaya A, Kaya Y, Topcu S, Gunaydin ZY, Kurt M, Tanboga IH, Kalkan K, Aksakal E. Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. *Angiology* 2014;65:51–56.
 20. Kaya MG, Akpek M, Lam YY, Yarlioglu M, Celik T, Gunebakmaz O, Duran M, Ulucan S, Keser A, Oguzhan A, Gibson MC. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. *Int J Cardiol* 2013;168:1154–1159.
 21. Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. *Circ Cardiovasc Qual Outcomes* 2009;2:656–662.
 22. Karabinos I, Koulouris S, Kranidis A, Pastromas S, Exadaktylos N, Kalofoutis A. Neutrophil count on admission predicts major in-hospital events in patients with a non-ST-segment elevation acute coronary syndrome. *Clin Cardiol* 2009;32:561–568.
 23. Acanfora D, Gheorghiadu M, Trojano L, Furgi G, Pasini E, Picone C, Papa A, Iannuzzi GL, Bonow RO, Rengo F. Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. *Am Heart J* 2001;142:167–173.
 24. Huehnergath KV, Mozaffarian D, Sullivan MD, Crane BA, Wilkinson CW, Lawler RL, McDonald GB, Fishbein DP, Levy WC. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. *Am J Cardiol* 2005;95:1492–1495.
 25. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation* 2006;113:1424–1433.
 26. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. *Circulation* 2007;116:392–398.
 27. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. *J Am Coll Cardiol* 2007;49:2364–2370.
 28. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. *Chest* 1996;110:325–332.
 29. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, Portnay EL, Marshalko SJ, Radford MJ, Krumholz HM. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. *J Am Coll Cardiol* 2003;42:736–742.